Highlights
- Subcutaneous blinatumomab achieved high remission rates (75-79%) in adults with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL).
- Both evaluated dosing regimens exhibited manageable safety profiles, with primary toxicities consistent with known blinatumomab effects.
- The 250 μg/500 μg subcutaneous regimen was selected as the recommended phase 2 dose due to balanced efficacy and tolerability.
- Subcutaneous administration offers logistical and potentially economic advantages that may drive a future trend in immunotherapy delivery.
Clinical Background and Disease Burden
